Market capitalization | $48.31m |
Enterprise Value | $-68.56m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.49 |
P/B ratio (TTM) P/B ratio | 0.46 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-54.55m |
Free Cash Flow (TTM) Free Cash Flow | $-46.00m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
2 Analysts have issued a Ikena Oncology Inc forecast:
2 Analysts have issued a Ikena Oncology Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.49 -0.49 |
107%
107%
|
|
EBITDA | -54 -54 |
27%
27%
|
EBIT (Operating Income) EBIT | -55 -55 |
28%
28%
|
Net Profit | -49 -49 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Head office | United States |
CEO | Mark Manfredi |
Employees | 10 |
Founded | 2016 |
Website | www.ikenaoncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.